Skip to content

Cervical Pessary in Women With Arrested Preterm Labor and Short Cervix

Cervical Pessary in Women With Arrested Preterm Labor and Short Cervix

Status
Withdrawn
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02849301
Acronym
PWK
Enrollment
0
Registered
2016-07-29
Start date
2016-07-31
Completion date
2018-03-31
Last updated
2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Birth

Brief summary

Preterm birth (PTB), defined as birth between 20 and 36 6/7 weeks, is responsible for the majority of the neonatal morbidity and mortality in the United States, and 35% of all U.S. healthcare spending on infants. Globally, about 28% of the 4 million annual neonatal deaths are directly attributable to PTB. Preterm labor (PTL) is the final pathway for about 50% of all PTB. Tocolytic agents are drugs that can slow or stop labor contractions in the attempt to delay births preceded by PTL. Primary tocolysis is defined as tocolysis given on initial presentation of women with PTL. In most of these women, PTL stops, but as their risk of PTB remains high, some have advocated use of maintenance tocolysis, i.e. tocolysis after arrested PTL. So far, no maintenance tocolytic agent has been shown to be beneficial in preventing PTB. The aim of this study is to evaluate the efficacy of maintenance tocolysis with Arabin pessary compared to standard care in singleton gestations with arrested PTL and with short transvaginal ultrasound (TVU) cervical length (CL) \<25mm

Interventions

Sponsors

Federico II University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* 18-50 ages * Singleton pregnancy * 24(0) - 34(6) weeks of gestation * Arrested preterm labor after primary tocolysis * Transvaginal ultrasound cervical length less than 25mm at admission * Agreement to regular follow-up and provision of written informed consent

Exclusion criteria

* pessary and no cerclage in situ * vaginal bleeding * placeta previa/accreta * multiple gestations * \<24(0) or \>24(6) weeks of gestation * Cervical dilatation greater than 3 cm * Chorioamnionitis * Major fetal abnormalities * Abruptio placentae * PPROM * Polyhydramnios or oligohydramnios * IUGR/FGR with or without Doppler abnormalities * Preeclampsia or pregnancy-related hypertension

Design outcomes

Primary

MeasureTime frame
Spontaneous preterm birth (SPTB)Less than 34 weeks gestation

Secondary

MeasureTime frameDescription
Admission to neonatal intensive care unitDelivery (at birth)
respiratory distress syndromeDelivery (at birth)
low birth weightDelivery (at birth)birth weight \<2500 grams
intraventricular hemorrhageBetween birth and 28 days of agegrade 3 or 4
Birth weightDelivery (at birth)mean birth weight in grams
Gestational age at deliveryDelivery (at birth)mean gestational age at delivery
LatencyDelivery (at birth)mean latency in days (from randomization to delivery)
neonatal mortalityBetween birth and 28 days of agedeath of a live-born baby within the first 28 days of life
Spontaneous preterm birth (SPTB)Less than 37,35,32,28 and 24 weeks gestation

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026